NASDAQ:RPRX

Royalty Pharma Competitors

$42.31
+0.37 (+0.88 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$41.43
Now: $42.31
$42.40
50-Day Range
$41.57
MA: $45.10
$48.03
52-Week Range
$34.80
Now: $42.31
$56.50
Volume1.06 million shs
Average Volume3.17 million shs
Market Capitalization$25.69 billion
P/E RatioN/A
Dividend Yield1.62%
BetaN/A

Competitors

Royalty Pharma (NASDAQ:RPRX) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying RPRX stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Royalty Pharma, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Royalty Pharma (NASDAQ:RPRX) and Johnson & Johnson (NYSE:JNJ) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Johnson & Johnson, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Johnson & Johnson031102.79

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Johnson & Johnson has a consensus target price of $180.6429, suggesting a potential upside of 12.03%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Johnson & Johnson.

Profitability

This table compares Royalty Pharma and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Johnson & Johnson21.01%34.64%13.40%

Earnings and Valuation

This table compares Royalty Pharma and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Johnson & Johnson$82.06 billion5.17$15.12 billion$8.6818.58

Johnson & Johnson has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Johnson & Johnson has increased its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.3% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Johnson & Johnson beats Royalty Pharma on 9 of the 12 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Pfizer (NYSE:PFE) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Pfizer, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Pfizer010302.23

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Pfizer has a consensus target price of $38.5714, suggesting a potential upside of 5.39%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Pfizer.

Profitability

This table compares Royalty Pharma and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Pfizer17.85%24.88%9.32%

Earnings and Valuation

This table compares Royalty Pharma and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Pfizer$51.75 billion3.94$16.27 billion$2.9512.41

Pfizer has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.3%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Pfizer beats Royalty Pharma on 6 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Merck & Co., Inc. (NYSE:MRK) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Merck & Co., Inc., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Merck & Co., Inc.021202.86

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Merck & Co., Inc. has a consensus target price of $95.9167, suggesting a potential upside of 25.69%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Royalty Pharma.

Profitability

This table compares Royalty Pharma and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Merck & Co., Inc.24.33%53.83%16.83%

Earnings and Valuation

This table compares Royalty Pharma and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Merck & Co., Inc.$46.84 billion4.12$9.84 billion$5.1914.70

Merck & Co., Inc. has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Merck & Co., Inc. has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Merck & Co., Inc. beats Royalty Pharma on 9 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and AbbVie (NYSE:ABBV) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
AbbVie121402.76

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. AbbVie has a consensus target price of $115.75, suggesting a potential upside of 7.63%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than AbbVie.

Profitability

This table compares Royalty Pharma and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
AbbVie18.16%439.24%13.22%

Earnings and Valuation

This table compares Royalty Pharma and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
AbbVie$33.27 billion5.71$7.88 billion$8.9412.03

AbbVie has higher revenue and earnings than Royalty Pharma.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.8%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and AbbVie has increased its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

AbbVie beats Royalty Pharma on 9 of the 12 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Eli Lilly and (NYSE:LLY) are both large-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.8%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Royalty Pharma has increased its dividend for 1 consecutive years and Eli Lilly and has increased its dividend for 1 consecutive years.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 2.5% of Royalty Pharma shares are held by insiders. Comparatively, 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Royalty Pharma and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Eli Lilly and24.01%166.45%15.18%

Analyst Ratings

This is a summary of current ratings and recommmendations for Royalty Pharma and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Eli Lilly and041102.73

Royalty Pharma presently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Eli Lilly and has a consensus target price of $196.40, suggesting a potential upside of 6.46%. Given Royalty Pharma's higher probable upside, equities research analysts plainly believe Royalty Pharma is more favorable than Eli Lilly and.

Earnings and Valuation

This table compares Royalty Pharma and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Eli Lilly and$22.32 billion7.93$8.32 billion$6.0430.54

Eli Lilly and has higher revenue and earnings than Royalty Pharma.

Summary

Eli Lilly and beats Royalty Pharma on 8 of the 11 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Dividends

Royalty Pharma pays an annual dividend of $0.68 per share and has a dividend yield of 1.6%. Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.1%. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 1 consecutive years and Bristol-Myers Squibb has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Royalty Pharma and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Royalty PharmaN/AN/AN/A
Bristol-Myers Squibb-0.11%27.48%10.77%

Analyst Recommendations

This is a summary of current ratings for Royalty Pharma and Bristol-Myers Squibb, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Royalty Pharma05402.44
Bristol-Myers Squibb031012.86

Royalty Pharma currently has a consensus target price of $51.8750, suggesting a potential upside of 22.61%. Bristol-Myers Squibb has a consensus target price of $74.6429, suggesting a potential upside of 19.22%. Given Royalty Pharma's higher probable upside, research analysts clearly believe Royalty Pharma is more favorable than Bristol-Myers Squibb.

Valuation & Earnings

This table compares Royalty Pharma and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty PharmaN/AN/AN/AN/AN/A
Bristol-Myers Squibb$26.15 billion5.35$3.44 billion$4.6913.35

Bristol-Myers Squibb has higher revenue and earnings than Royalty Pharma.

Summary

Bristol-Myers Squibb beats Royalty Pharma on 8 of the 12 factors compared between the two stocks.


Royalty Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$161.25+1.1%$424.52 billion$82.06 billion25.35
Pfizer logo
PFE
Pfizer
2.4$36.60+1.7%$204.14 billion$51.75 billion23.61Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$76.31+1.1%$193.09 billion$46.84 billion16.88News Coverage
AbbVie logo
ABBV
AbbVie
2.8$107.54+1.3%$189.79 billion$33.27 billion22.74Analyst Report
Eli Lilly and logo
LLY
Eli Lilly and
2.1$184.49+1.0%$176.92 billion$22.32 billion30.15
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$62.61+1.1%$139.87 billion$26.15 billion-569.13Analyst Upgrade
News Coverage
Zoetis logo
ZTS
Zoetis
2.2$159.85+0.1%$75.93 billion$6.26 billion47.43
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.48+0.5%$20.50 billion$1.30 billion24.99Analyst Upgrade
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$161.40+0.3%$9.09 billion$2.16 billion50.91Insider Selling
Perrigo logo
PRGO
Perrigo
2.5$40.53+0.8%$5.41 billion$4.84 billion-675.39Analyst Report
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.63+3.3%$3.40 billion$114.62 million-7.51Analyst Report
Analyst Revision
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$68.25+0.4%$2.99 billion$421.03 million24.03Analyst Downgrade
Analyst Revision
Gap Down
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$22.68+1.0%$2.66 billion$306.49 million25.48Insider Selling
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31+0.7%$1.50 billion$392.76 million11.75Analyst Revision
News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20+1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Omeros logo
OMER
Omeros
1.4$18.23+2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$19.27+0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.96+12.7%$373.27 million$16.54 million-3.24High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.55+2.8%$358.06 million$111.39 million25.36News Coverage
Gap Down
Lannett logo
LCI
Lannett
2.0$4.95+1.6%$204.94 million$545.74 million-6.87Analyst Upgrade
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.36+0.5%$166.75 million$15.96 million-2.64Unusual Options Activity
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.17+4.1%$47.30 million$47.53 million-14.41News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.